Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Immix Biopharma, Inc. (IMMX : NSDQ)

• Company Description    Immix Biopharma Inc. is a biopharmaceutical company pioneering Tissue Specific Therapeutics (TM) targeting oncology and immuno-dysregulated diseases. Immix Biopharma Inc. is based in LOS ANGELES. Number of Employees: 21

• Price / Volume Information    Yesterday's Closing Price: $8.15 Daily Weekly Monthly 20 Day Moving Average: 1,663,442 shares Shares Outstanding: 71.54 (millions) Market Capitalization: $583.04 (millions) Beta: 0.24 52 Week High: $15.10 52 Week Low: $2.85 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -30.34% -29.61% 12 Week -4.68% -7.00% Year To Date 55.83% 42.62%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11400 WEST OLYMPIC BLVD SUITE 200 - LOS ANGELES,CA 90064 USA ph: 310-651-8041 fax: - None http://www.immixbio.com

• General Corporate Information    Officers Ilya Rachman - Chief Executive Officer Gabriel Morris - Chief Financial Officer; President and Director Jason Hsu - Director Magda Marquet - Director Helen C. Adams - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 45258H106 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/06/26 Share - Related Items Shares Outstanding: 71.54 Most Recent Split Date: (:1) Beta: 0.24 Market Capitalization: $583.04 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 3.90% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/06/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.55 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 18.18% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 09/30/26 - - 06/30/26 - -38.44 03/31/26 - -73.24 ROA 09/30/26 - - 06/30/26 - -34.72 03/31/26 - -59.20 Current Ratio 09/30/26 - - 06/30/26 - 25.13 03/31/26 - 8.75 Quick Ratio 09/30/26 - - 06/30/26 - 25.13 03/31/26 - 8.75 Operating Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Net Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Pre-Tax Margin 09/30/26 - - 06/30/26 - - 03/31/26 - - Book Value 09/30/26 - - 06/30/26 - 3.20 03/31/26 - 1.59 Inventory Turnover 09/30/26 - - 06/30/26 - - 03/31/26 - - Debt-to-Equity 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00 Debt-to-Capital 09/30/26 - - 06/30/26 - 0.00 03/31/26 - 0.00

Powered by Zacks Investment Research ©